On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Relax, Robots Have it Handled

  • Massive opportunity ahead says CEO of Autonomous Security Robot maker Knightscope
  • Wide ranging interview discloses vast potential in federal applications
  • Knightscope’s state of the art ASRs provide cost effective 24/7/365 security
The rise of machines has arrived. Relax, it isn’t the rise of Skynet, the malevolent neural network superintelligence system from the movie Terminator. This rise of machines has no malice. In fact, these machines benefit society by uniquely combining robotics, self-driving technology, and artificial intelligence to reduce crime as well as provide safety, security, and real-time data in a multitude of settings. With the rise of its Autonomous Security Robots (“ASRs”), tech innovator Knightscope is on track to revolutionize the $500 billion security industry. The company is rapidly displacing moribund security duties across the country and its ASRs are already on-guard in federal government facilities, public institutions, and numerous Fortune 1000 companies. Knightscope’s ASRs operate 24/7/365 providing real-time access to data around the clock and can capture 90 terabytes of data each year. These machines also feature 360-degree eye-level HD video streaming, people detection, facial recognition, automatic license plate recognition, thermal anomaly detection, and automatic signal detection. Not only does the presence of ASRs help deter crime, but these sentries also help law enforcement reaction times, provide resolution to any legal matters with recorded video as well as provide training and operational improvement opportunities. On top of all the technological wizardry, Knightscope’s ASRs save customers money by cost effectively augmenting the high costs of security. The future looks bright for Knightscope. In a recent IPO Edge Fireside Chat with Knightscope CEO William Santana Li was quite bullish on the outlook. He sees a massive opportunity ahead, especially with the federal government. In the interview he stated, “The federal government is going to be, I think, a long term very very large client for us.” As Mr. Li outlined, just think of all the federal applications that need augmented 24/7/365 security. Military bases and their storage facilities, national parks, FEMA warehouses, Federal courthouses – the list of applications is seemingly endless, and the company is on a roll. Knightscope has brought the future to the present with its innovation and market disrupting technology. The company is rapidly gaining traction, deploying its sentries to public and private entities, saving customers money, and providing improved security across the country. There’s certainly nothing to fear from this rise of machines. For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.